Ulcerative colitis:: Analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?)

被引:0
|
作者
Özdil, S [1 ]
Akyüz, F [1 ]
Pinarbasi, B [1 ]
Demir, K [1 ]
Karaca, C [1 ]
Boztas, G [1 ]
Kaymakoglu, S [1 ]
Mungan, Z [1 ]
Besisik, F [1 ]
Cakaloglu, Y [1 ]
Ökten, A [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Gastroenterol, TR-34590 Istanbul, Turkey
关键词
ulcerative colitis; treatment; extraintestinal manifestations;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Evaluation of clinical, demographic and epidemiologic features of ulcerative colitis and therapy response of these patients. Methodology: Retrospectively, 116 patients (64.7% female) were enrolled in this study. Mean age and mean follow-up period were 36+/-16, 5+/-2 years, respectively. Results: The most common anatomic involvement was pancolitis (60.3%) and the others were as follows: left side 25%, rectum 13.8% and ileum (backwash ileitis) 0.9%. Extraintestinal manifestations were observed in 42.2% of patients (sacroiliitis 12%, primary sclerosing cholangitis 7.6%, pyoderma gangrenosum 2.4%, peripheral arthropathy 1.6%, autoimmune hepatitis 1.6%, steatosis 12.9%, gallstone 0.8%, perianal fistulas 0.8%, sagittal sinus thrombosis 0.8%, psoriasis 0.8%). Multiple extraintestinal manifestations were observed (primary sclerosing cholangitis + pyoderma gangrenosum) in 2 patients. Colonic perforation due to toxic megacolon was observed in only one patient during follow-up period. The mean period for remission was 3.7 months in 72% of patients with pancolitis by the treatment of 5-aminosalicylic acid (5-ASA) (2-3gr/day) + methylprednisolone (1mg/kg/day) +/- (for maintenance of remission) azathioprine (AZT) (1.5-2mg/kg/day); 3.7 months in 72% of left-sided colitis by 5-ASA +/- corticosteroid enemas +/- methylprednisolone (1mg/kg/day) +/- (for maintenance of remission) AZT (1.5-2mg/kg/day) and 3.7 months in 62.5% of patients with distal colitis by 5-ASA (PO +/- enema) +/- corticosteroid enemas. Colectomy was performed on 7 patients refractory to these treatments. Six patients (4 of them had pancolitis) were treated with cyclosporine (Cys) (4mg/kg/day, PO). Only one patient, a non-responder to Cys therapy, had colectomy. The mean remission time was 4.7 months in 80.6% of patients with extraintestinal involvement and 3.2 months in 71.2% of patients without extraintestinal involvement (P=0.002). Conclusions: Medical therapy was generally enough for the treatment. Cys and/or surgery can be another choice for the patients that do not respond to the medical therapy. Extraintestinal manifestations do not change the remission rate, but prolong the time to catch remission.
引用
收藏
页码:768 / 770
页数:3
相关论文
共 43 条
  • [1] Joint Extraintestinal Manifestations in Ulcerative Colitis
    Dorofeyev, A. E.
    Vasilenko, I. V.
    Rassokhina, O. A.
    DIGESTIVE DISEASES, 2009, 27 (04) : 502 - 510
  • [2] Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
    Rubin, David T.
    Reinisch, Walter
    Greuter, Thomas
    Kotze, Paulo G.
    Pinheiro, Marcia
    Mundayat, Rajiv
    Maller, Eric
    Fellmann, Marc
    Lawendy, Nervin
    Modesto, Irene
    Vavricka, Stephan R.
    Lichtenstein, Gary R.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [3] Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy
    Thomas, PD
    Keat, AC
    Forbes, A
    Ciclitira, PJ
    Nicholls, RJ
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (09) : 1001 - 1005
  • [4] Drug allergy is Associated with the Development of Extraintestinal Manifestations in Patients with Ulcerative Colitis
    Toledo-Maurino, J. J.
    Yamamoto-Furusho, J. K.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 52 (01) : 35 - 38
  • [5] Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy
    Goudet, P
    Dozois, RR
    Kelly, KA
    Ilstrup, DM
    Phillips, SF
    DIGESTIVE SURGERY, 2001, 18 (01) : 51 - 55
  • [6] Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab
    Carpineti, Claudia
    Mugheddu, Cristina
    Cadoni, Marta
    Anedda, Jasmine
    Atzori, Laura
    Fantini, Massimo C.
    Onali, Sara
    INFLAMMATORY BOWEL DISEASES, 2023, : 1512 - 1514
  • [7] Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis
    Nomura, Osamu
    Osada, Taro
    Shibuya, Tomoyoshi
    Ishikawa, Dai
    Haga, Keiichi
    Kodani, Tomohiro
    Sakamoto, Naoto
    Ogihara, Tatsuo
    Yamaji, Ken
    Watanabe, Sumio
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (01) : 21 - 28
  • [8] Primary Sclerosing Cholangitis and Extraintestinal Manifestations in Patients with Ulcerative Colitis and Ileal Pouch–Anal Anastomosis
    Hans H. Wasmuth
    Gerd Tranø
    Birger H. Endreseth
    Arne Wibe
    Astrid Rydning
    Helge E. Myrvold
    Journal of Gastrointestinal Surgery, 2010, 14 : 1099 - 1104
  • [9] Extraintestinal manifestations in inflammatory bowel disease:: differences between Crohn's disease and ulcerative colitis
    Mendoza, JL
    Lana, R
    Taxonera, C
    Alba, C
    Izquierdo, S
    Díaz-Rubio, M
    MEDICINA CLINICA, 2005, 125 (08): : 297 - 300
  • [10] Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
    Kwon, Yiyoung
    Kim, Eun Sil
    Choe, Yon Ho
    Kim, Mi Jin
    FRONTIERS IN PEDIATRICS, 2022, 10